Impact of AFO (ankle foot orthosis) Design on Calf Circumference by Meier, Robert H. et al.
Chapman University
Chapman University Digital Commons
Physical Therapy Faculty Articles and Research Physical Therapy
2014








Follow this and additional works at: http://digitalcommons.chapman.edu/pt_articles
Part of the Physical Therapy Commons
This Article is brought to you for free and open access by the Physical Therapy at Chapman University Digital Commons. It has been accepted for
inclusion in Physical Therapy Faculty Articles and Research by an authorized administrator of Chapman University Digital Commons. For more
information, please contact laughtin@chapman.edu.
Recommended Citation
Meier RH, Ruthsatz DC, Cipriani D (2014). Impact of AFO (ankle foot orthosis) design on calf circumference. Lower Extremity
Review, 6(10), 29-35.
Impact of AFO (ankle foot orthosis) Design on Calf Circumference
Comments
This article was originally published in Lower Extremity Review, volume 6, issue 10, in 2014.
Copyright
Lower Extremity Review Magazine
This article is available at Chapman University Digital Commons: http://digitalcommons.chapman.edu/pt_articles/38
Impact of AFO design
on calf circumference
Preliminary research suggests the use of
a kinetic return ankle foot orthosis is as-
sociated with small but significant short-
term increases in calf circumference,
which in turn suggests this type of device
might reduce or protect against the risk
of disuse muscle atrophy.
By Robert H. Meier, CO, BOCO; David C. Ruthsatz, CO, CPA; and Daniel
Cipriani, PT, PhD
Atrophy of the calf muscle group in patients with neuromuscular in-
volvement has been seen clinically. Evidence clearly demonstrates
the contribution of the neuromuscular condition for calf muscle at-
rophy, yet only a single case study demonstrated the contribution
of a molded ankle foot orthosis (MAFO) to calf circumference. It is
not known if a more dynamic AFO would have any influence on calf
circumference. The objective of this study was to determine the in-
fluence of a dynamic AFO on calf circumference and, potentially,
the risk of calf muscle atrophy.
Calf group atrophy in patients with neuromuscular involvement
is a common clinical observation and may be the result of a combi-
nation of factors, including the neuromuscular condition as well as
the use of a MAFO to manage foot drop. A literature search (via
PubMed), which we conducted using numerous key words and
phrases (eg, AFO calf atrophy, CVA calf atrophy, neuro-deficit calf
atrophy), yielded results indicating calf muscle group atrophy can
occur secondary to cerebrovascular accident1 but only one case
study2 specifically linked calf atrophy to MAFO usage, in this case
in a patient with a diagnosis of clubfoot. Several studies identified
significant reduction in muscle activity of the tibialis anterior while
wearing an AFO, which, with prolonged usage, could lead to muscle
atrophy.3-5
The search also revealed numerous studies6-8 suggesting that
immobilization may be a causative factor leading to disuse atrophy
of muscle mass and strength. While custom-molded AFOs do not
induce 100% immobilization because they are fit on soft tissue,
these rigid structures provide functional immobilization. Even artic-
ulating ankle MAFOs immobilize foot complex inversion and ever-
sion, abduction and adduction, and plantar flexion, while allowing
only dorsiflexion. It is likely that MAFOs may contribute to the de-
velopment of disuse atrophy in neuromuscular deficit patients.   
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Reductions in tibialis anterior muscle
activity associated with wearing an
ankle foot orthosis could, with prolonged
usage, lead to muscle atrophy.
Shutterstock.com #35070943
Review of the calf group function
Before studying atrophy of the calf group in neuro-involved patients,
a review of the normal closed chain function of the gastrocsoleus
complex was completed.9 Both the gastrocnemius and soleus mus-
cles are activated at initial contact during gait secondary to syner-
gistic firing of the anterior tibialis muscle, and this results in
deceleration of the forefoot to the ground. At the same time, cal-
caneal eversion triggers a stretch reflex to both the gastroc and
soleus muscles. The gastrocsoleus complex, along with the poste-
rior tibialis muscle, eccentrically decelerates frontal plane calcaneal
eversion, which is a component of pronation. This helps to control
frontal plane ankle eversion and transverse plane internal rotation
of the tibia.
Transitioning into the second rocker of gait, the muscle group
continues to work eccentrically in midstance. The soleus deceler-
ates the progression of the tibia over the fixed foot (ankle dorsiflex-
ion motion), allowing proximal inertial forces to create knee
extension. The gastrocnemius, which originates above the knee,
works to modulate the rate of knee extension being created by the
soleus and by inertia. In late midstance the gastroc and soleus mus-
cles work to facilitate inversion of the calcaneus, supinating the foot
so it can be a more efficient lever arm for propulsion.
In the third rocker, or the propulsive phase, of gait, the gastroc-
soleus complex works concentrically to lift the heel off the ground,
taking advantage of proximal inertial forces, and then to concentri-
cally plantar flex the ankle (creating 39% to 47% of propulsion10),
propelling the foot off the ground and advancing the limb though
space. In the process, the muscle complex helps maintain a more
rigid supinated foot to create a more efficient propulsive lever arm,
and facilitates external tibial rotation and ankle inversion. The com-
plex turns off as the toes leave the ground and stays off until the
next initial contact made by that limb.
This review reinforced the concept that the calf group functions
in all three planes during the stance phase of gait, which led to the
hypothesis that simply immobilizing the calcaneus in a subtalar neu-
tral position would diminish the functional capacity of the calf mus-
cle group and increase the risk of disuse atrophy. 
Study design
The study was designed to measure calf circumference in patients
who had worn MAFOs and were being transitioned into a more dy-
namic AFO design, a kinetic return AFO (KRAFO). Patient selection
included all consecutive patients presenting for new AFOs at a sin-
gle O&P facility. A single orthotist measured calf circumference in
all patients to minimize intrarater variability, measuring at maximum
calf circumference and 2.54 cm above and 2.54 cm below that
mark. 
A subjective patient survey was administered to determine the
patient’s level of satisfaction and level of function while wearing their
MAFOs. The survey (Figure 1) asked for patient estimates of total
device wear time, device wear time leading to fatigue, and distance
capacity; it also asked patients to use a 1-to-10 rating scale for
seven different criteria related to patient satisfaction and percep-
tions of their ability to function in the devices. Gait speed was also
measured in seconds with a stopwatch while patients walked 10-
meter timed tests both in their existing device and after fitting of the
KRAFOs. All of the data were locked after acquisition to avoid influ-
encing the follow-up tests.  
During the test period, patients were instructed to wear the
KRAFO during waking hours or to tolerance. After eight weeks, the
patient’s calf circumference and walking speed were reassessed by
the same rater following the same protocols to detect any differ-
ences in circumference measurements occurring secondary to the
switch to a KRAFO.  At the same time, the subjective patient survey
was administered again to determine the patient’s level of satisfac-
tion and level of function while in the KRAFO. This second set of
Continued from page 29
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FOLLOW-UP VISIT AT 8 WEEKS ± 2 DAYS: PATIENT DATA
Hours the AFO is worn during day:  4  6  8  10  12  waking hours
Hours the AFO is worn before becoming fatigued:  4  6  8  10  12  waking hours
Distance capacity (in yards):  10  50  100  500  1,000 +     
Rate the following regarding the carbon composite AFO (1 being the lowest and 10 the highest)
1. Ability to conceal the AFO 1 2 3 4 5 6 7 8 9 10
2. Overall comfort wearing the AFO 1 2 3 4 5 6 7 8 9 10
3. Standing balance with the AFO 1 2 3 4 5 6 7 8 9 10
4. The weight of the AFO while walking 1 2 3 4 5 6 7 8 9 10
5. Stability during walking with the AFO 1 2 3 4 5 6 7 8 9 10
6. Involved side leg strength at the end of the day 1 2 3 4 5 6 7 8 9 10
7. Overall satisfaction with the current device 1 2 3 4 5 6 7 8 9 10
Figure 1.  Satisfaction survey form.
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time to fatigue was nine hours in the MAFOs (range, 4-16 h, with one patient at 16 h) compared
with 15.11 h (range, 10-16 h, with 16 patients at 16 h) in the KRAFO, a statistically significant dif-
ference (p < .001). Mean distance capacity reported for the MAFOs was 882.35 yards (range, 500
to 1000 yards, with 15 patients at 1000 yards) compared with 1000 yards (all 19 at 1000 yards)
in the KRAFOs, a statistically significant difference (p = .041). 
Ease of use. Patients gave the KRAFOs significantly higher ratings than the MAFOs for ability
to conceal the device, comfort, and satisfaction with the device’s weight (p < .001). Mean rating
for ability to conceal the device was 6.32 (range, 1-9) for the MAFOs and 8.79 (range, 8-10) for
the KRAFOs. Mean rating for comfort was 5.89 for the MAFOs (range, 1-9) and 9 for the KRAFOs
(range, 7-10). Mean satisfaction with the weight of the device was rated at 6.37 (range, 1-10) for
the MAFOs and 9 (range, 2-10) for the KRAFOs. 
Patient perceptions. Patients gave the KRAFOs significantly higher ratings than the MAFOs
for perceived balance, perceived stability during gait, and perceived strength (p < .001). Perceived
balance was given a mean rating of 5.89 (range, 2-9) for the MAFOs and 8.94 (range, 7-10) for the
KRAFOs. The mean rating for perceived stability during gait was 6.39 (range, 5-9) for the MAFOs
and 8.74 (range, 7-10) for the KRAFOs. Perception of strength was given a mean rating of 6 (range,
2-8) for the MAFOs and 8.58 (range, 7-10) for the KRAFOs. 
Finally, the mean rating for overall satisfaction with the device was 6.32 (range, 5-8) for the
MAFOs compared with 9.16 (range, 7-10) for the KRAFOs. This difference was statistically signifi-
cant (p < .001).
Discussion
This study attempted to determine if KRAFOs could influence calf circumference in patients who
had habitually worn MAFOs. In addition, it examined walking speed and subjective perceptions of
the patients when wearing KRAFOs and MAFOs.
The data suggest that use of a KRAFO may engage the calf muscles during physical activity.
The slight but statistically significant increase in mean calf size observed over the eight-week period
is very encouraging, especially considering that muscle hypertrophy does not begin until at least
data was compared with the first set and analyzed using a paired samples T-test. 
Objective study results 
All study participants presented to a single orthotist in a privately owned O&P clinical setting over
a 14-month period with prescriptions from various physicians for replacement AFOs. Although 38
patients were initially enrolled in the study, only 19 patients were available for the eight-week (plus
or minus two days) follow-up assessment. Patients had worn MAFOs an average of 17.44 months
(range, 1-24 months) prior to the start of the study, and presented with foot drop resulting from 12
different neuromuscular diagnoses. The right side was involved in seven patients, the left side was
involved in nine patients, and three patients were affected bilaterally. MAFO design included solid
ankle (n = 6) (Figure 2), posterior leaf spring (n = 10), and articulating ankle/plantar flexion stop 
(n = 3) AFOs. These patients were switched to one of three KRAFOs (Figure 3) that provided dif-
ferent levels of support; patient body type and proximal deficits determined the level of support
needed. All KRAFOs were customized, including, at a minimum, the addition of a firm, prefabricated
foot orthotic shell on top of the AFO footplate. 
Calf circumference. In the 19 patients, mean calf circumference was 324.35 mm (minimum
= 266.7 mm, maximum = 419.1 mm) at the start of the study and 328.95 mm (minimum = 279.4
mm, maximum = 425.45 mm) after eight weeks in KRAFOs. The difference between measure-
ments was statistically significant. 
Walking speed. Patients tended to walk more slowly while wearing the MAFOs, completing
the 10-m walking distance in 14.99 seconds (range, 10.8-18.8), compared with 14.58 seconds
(range, 12.5-17.8) while wearing the KRAFOs (p < .001). 
Subjective study results 
Subjective study results are reported in Table 1.
Device use. The self-reported mean number of hours per day (h/d) that patients wore the
AFOs was 13.26 h/d for the MAFOs (range, 8-16 h/d, with eight patients at 16 h/d) compared with
15.16 h/d (range, 10-16 h/d, with 16 patients at 16 h/d) for the KRAFOs. This difference was sta-
tistically significant (p < .001). (A patient response of “waking hours” was calculated as 16 h/d.)
Functional improvement. The self-reported mean
Figure 2. Solid ankle molded ankle foot orthosis.
Figure 3. Kinetic return ankle foot orthosis.
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three to four weeks of muscle overload or resistance.11 Any addi-
tional calf muscle activity associated with KRAFO use is likely related
to two primary design differences between MAFOs and KRAFOs:
KRAFOs allow normal biomechanical function in the talocalcaneal
and talotarsal joints, while the rearfoot is relatively immobilized in
MAFOs, and KRAFOs are designed to return energy during the third
rocker to assist with propulsion, while MAFOs are not. 
Patients also walked slightly but significantly faster when wear-
ing the KRAFOs than while wearing the MAFOs, even though they
were less familiar with the KRAFOs, a finding that suggests improved
function. This is consistent with the subjective ratings of perceived
stability during gait, which were significantly higher for the KRAFOs
than the MAFOs. In addition, there was less variability between pa-
tients with regard to gait speed for the KRAFOs than the MAFOs,
suggesting a more consistent gait with the KRAFOs.
Other subjective ratings were also significantly higher for the
KRAFOs than the MAFOs. This suggests the KRAFOs’ light weight
and low profile are associated with an improved sense of balance,
strength, and gait stability. Higher levels of overall satisfaction for
the KRAFOs than the MAFOs also are consistent with the improved
gait speeds and improved sense of comfort and mobility.
Study limitations 
The study does not identify causative factors leading to calf hyper-
trophy. The authors assume it is a result of the functional design of
the KRAFO, but it could also be secondary to the patient’s percep-
tion of comfort, leading to longer wearing times and greater walking
distances in the KRAFO. And it may be all of these factors. 
The study did not document patient weight during either test
session. It is possible that patient weight loss due to an increase in
activity in the KRAFO might have had a negative effect on calf cir-
cumference, potentially offsetting increases related to muscle de-
velopment. No clinically relevant changes in edema status were
noted between the two testing sessions. An increase in walking
would tend to decrease edema, so if that occurred, that also would
have had a negative impact on gains shown in calf circumference.  
The subjective assessment of distance capacity may not have
offered enough choices to re-
flect patients’ actual activity
levels. Fourteen of the 19 pa-
tients rated their capacity at
1000 yards or more in the
MAFOs, while all 19 rated
their distance capacity at
1000 yards or more in the
KRAFOs. Future study de-
signs should include options
such as longer measures of
distance capacity. 
The study was designed
with a very narrow window
for follow-up, at eight weeks
plus or minus two days, and
data were not acquired if the
follow-up was outside the
four-day window. A slightly
wider window of plus or minus five days would have increased par-
ticipation rates at follow-up. 
Conclusions
Some design features commonly used in MAFOs to create stability
lead to areas of immobilization that may increase a patient’s risk of
disuse atrophy in the calf muscles. This study found that use of a ki-
netic return AFO is associated with small but significant short-term
increases in calf circumference, which suggests this type of device
might reduce or protect against the risk of disuse atrophy. Subjective
ratings of patient perceptions also suggest this device may make
the patient more functionally stable. 
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Table 1. Satisfaction survey results.
